Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

463 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis.
Krueger JG, Kircik L, Hougeir F, Friedman A, You X, Lucas N, Greenberg SJ, Sweetser M, Castro-Borrero W, McCroskery P, Elkins J. Krueger JG, et al. Adv Ther. 2016 Jul;33(7):1231-45. doi: 10.1007/s12325-016-0353-2. Epub 2016 Jun 1. Adv Ther. 2016. PMID: 27251051 Free PMC article. Clinical Trial.
Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: a randomized double-blind placebo-controlled clinical trial.
Alavi A, Prens EP, Kimball AB, Frew JW, Krueger JG, Mukhopadhyay S, Gao H, Ranganathan U, Ivanoff NB, Hernandez Daly AC, Zouboulis CC. Alavi A, et al. Among authors: krueger jg. Br J Dermatol. 2024 Sep 18;191(4):508-518. doi: 10.1093/bjd/ljae144. Br J Dermatol. 2024. PMID: 38576350 Clinical Trial.
Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis.
Boy MG, Wang C, Wilkinson BE, Chow VF, Clucas AT, Krueger JG, Gaweco AS, Zwillich SH, Changelian PS, Chan G. Boy MG, et al. Among authors: krueger jg. J Invest Dermatol. 2009 Sep;129(9):2299-302. doi: 10.1038/jid.2009.25. Epub 2009 Feb 19. J Invest Dermatol. 2009. PMID: 19225543 Free article. Clinical Trial. No abstract available.
Differential Pharmacodynamic Effects on Psoriatic Biomarkers by Guselkumab Versus Secukinumab Correlate with Long-Term Efficacy: An ECLIPSE Substudy.
Blauvelt A, Chen Y, Branigan PJ, Liu X, DePrimo S, Keyes BE, Leung M, Fakharzadeh S, Yang YW, Muñoz-Elías EJ, Krueger JG, Langley RG. Blauvelt A, et al. Among authors: krueger jg. JID Innov. 2024 Jun 26;4(5):100297. doi: 10.1016/j.xjidi.2024.100297. eCollection 2024 Sep. JID Innov. 2024. PMID: 39224116 Free PMC article.
Hepatocyte Growth Factor Has Unique Functions in Keratinocytes that Differ from those of IL-17A and TNF and May Contribute to Inflammatory Pathways in Hidradenitis Suppurativa.
Shishido-Takahashi N, Garcet S, Cueto I, Miura S, Li X, Rambhia D, Kunjravia N, Hur HB, Lee YI, Ham S, Anis N, Kim J, Krueger JG. Shishido-Takahashi N, et al. Among authors: krueger jg. J Invest Dermatol. 2024 Jul 20:S0022-202X(24)01918-3. doi: 10.1016/j.jid.2024.07.005. Online ahead of print. J Invest Dermatol. 2024. PMID: 39038532
Spesolimab Reduces Inflammation in Generalized Pustular Psoriasis: Molecular Characterization of Flare Treatment in EFFISAYIL 1.
Farag A, Visvanathan S, Bachelez H, Morita A, Lebwohl MG, Barker JN, Choon SE, Burden AD, Tsai TF, Leparc G, Delic D, Lang B, Thoma C, Krueger JG. Farag A, et al. Among authors: krueger jg. J Invest Dermatol. 2024 Jul 14:S0022-202X(24)01888-8. doi: 10.1016/j.jid.2024.05.034. Online ahead of print. J Invest Dermatol. 2024. PMID: 39004117
463 results